Skip to main content
. Author manuscript; available in PMC: 2013 Dec 26.
Published in final edited form as: JAMA. 2013 Jun 26;309(24):10.1001/jama.2013.6882. doi: 10.1001/jama.2013.6882

Figure 3.

Figure 3

Estimating the Use of Prostate Cancer Treatments for Men Least Likely to Benefit

Among Medicare beneficiaries diagnosed with prostate cancer, the use of advanced treatment technologies increased from 13% (95% CI, 12%–14%) in 2004 to 24% (95% CI, 24%–25%) in 2009 for men unlikely to die of prostate cancer (P <.001, Pearson χ2 test). At the same time, the use of prior standard treatments for these patients decreased 8% (P <.001, Pearson χ2 test).